Načítá se...
Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...
Uloženo v:
| Vydáno v: | BMC Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490602/ https://ncbi.nlm.nih.gov/pubmed/26137986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0398-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|